Search

Your search keyword '"Louis J. Kim"' showing total 2 results
Start Over Author "Louis J. Kim" Publisher american society of neuroradiology (asnr)
2 results on '"Louis J. Kim"'

1. Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms

Author

M. Litao, R. W. Crowley, Andrew F. Ducruet, Bradley A. Gross, Peter Kan, Christopher S. Ogilvy, Stephen R. Chen, Clemens M. Schirmer, Keaton Piper, Omar Tanweer, Maxim Mokin, Howard A. Riina, Justin R Mascitelli, Jeremiah N. Johnson, C. McDougall, Ajith J. Thomas, A. Enriquez-Marulanda, Jan-Karl Burkhardt, Adib A. Abla, C Griessenauer, Benjamin K Hendricks, Vivek J. Srinivasan, Felipe C. Albuquerque, Louis J. Kim, Georgios A Maragkos, Lee A Birnbaum, Aditya Srivatsan, Michael R. Levitt, Shamsher S. Dalal, Ethan A. Winkler, and Brian T Jankowitz

Subjects
Adult, Male, medicine.medical_specialty, Subarachnoid hemorrhage, medicine.medical_treatment, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Aneurysm, Blood vessel prosthesis, Atlas (anatomy), Product Surveillance, Postmarketing, medicine, Humans, Radiology, Nuclear Medicine and imaging, cardiovascular diseases, Embolization, Aged, Retrospective Studies, Coil embolization, Interventional, business.industry, Stent, Intracranial Aneurysm, Retrospective cohort study, Middle Aged, medicine.disease, Embolization, Therapeutic, Blood Vessel Prosthesis, Treatment Outcome, medicine.anatomical_structure, cardiovascular system, Female, Stents, Neurology (clinical), Radiology, business, 030217 neurology & neurosurgery
Abstract

BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (

Published
2020

2. Incidence of Microemboli and Correlation with Platelet Inhibition in Aneurysmal Flow Diversion

Author

Laligam N. Sekhar, D Hallam, Basavaraj Ghodke, Michael R. Levitt, and Louis J. Kim

Subjects
Thienopyridine, Statistics as Topic, Platelet inhibition, Platelet reactivity, P2Y12, Aneurysm, Risk Factors, medicine, Humans, Radiology, Nuclear Medicine and imaging, Retrospective Studies, Interventional, Flow diversion, business.industry, Incidence (epidemiology), Retrospective cohort study, medicine.disease, Blood Vessel Prosthesis, Radiography, Treatment Outcome, Intracranial Embolism, Anesthesia, Stents, Neurology (clinical), business, Platelet Aggregation Inhibitors
Abstract

Flow-diverting stents have been associated with embolic and hemorrhagic complications, but the rate of procedure-related microemboli is unknown. Using transcranial Doppler sonography, we measured the rate of microemboli in 23 patients treated with flow-diverting stents. Patients received preprocedural dual antiplatelet medications and intraprocedural heparinization. Point-of-care platelet reactivity testing was performed before the procedure, and nonresponders (>213 P2Y12/ADP receptor reactivity units) received additional thienopyridine. Transcranial Doppler sonography was performed within 12–24 hours. Microemboli were detected in 3 patients (13%), 2 of whom were initially nonresponders. There was no association between the presence of microemboli and procedural or neurologic complications, aneurysm size, number of stents, or procedure time. Eight procedures (34.8%) required additional thienopyridine for inadequate platelet inhibition, and 3 required further treatment for persistent nonresponse to point-of-care platelet reactivity testing. There were 6 technical and 2 postoperative complications; none were associated with inadequate platelet inhibition or microemboli. The combination of routine point-of-care platelet reactivity testing and postprocedural microembolic monitoring may help identify patients at risk for thromboembolic complications after flow-diverting stents.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results